GlassScriptPhysician profile
Stephanie J Morris
NPI 1528263522
$9,576.76
in general payments reported to CMS, 2019-2025
40 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,399 · 2020: $600 · 2021: $1,245 · 2022: $1,688 · 2023: $1,802 · 2024: $1,534 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272 · Education: $198 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,272.21 |
| Education | $198.00 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,218.62 | 2019-2025 | Enbrel, Prolia, Evenity |
| Abbvie INC. | $1,227.35 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,078.18 | 2019-2024 | |
| Janssen Biotech, INC. | $779.85 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $579.92 | 2019-2024 | Cimzia |
| Pfizer INC. | $578.43 | 2019-2023 | |
| Lilly USA, LLC | $305.68 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $274.33 | 2019-2023 | Orencia |
| Glaxosmithkline, LLC. | $233.49 | 2019-2023 | Benlysta |
| Ani Pharmaceuticals, INC. | $203.74 | 2022-2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $188.73 | 2019-2024 | Actemra, Rituxan |
| Astrazeneca Pharmaceuticals LP | $185.74 | 2021-2024 | Saphnelo |
| Genzyme Corporation | $156.51 | 2019-2024 | |
| Radius Health, INC. | $148.63 | 2019-2023 | Tymlos |
| Celgene Corporation | $141.25 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.